 |
|
|
| |
Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities
|
| |
| |
EASL 2022 June 22-26 London
Michael Shen, Zhixin Zong, Naqvi Mohammed, Katie Zomorodi, Luisa M Stamm, William Delaney, Nicole White
Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
